Eli Lilly Valuation
| LILY34 Stock | BRL 180.70 5.96 3.41% |
At this time, the firm appears to be undervalued. Eli Lilly shows a prevailing Real Value of R$202.73 per share. The current price of the firm is R$180.7. Our model computes the value of Eli Lilly from reviewing the firm fundamentals such as Current Valuation of 1.91 T, profit margin of 0.22 %, and Shares Outstanding of 28.51 B as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 180.7 | Real 202.73 | Hype 180.7 | Naive 179.79 |
The real value of Eli Stock, also known as its intrinsic value, is the underlying worth of Eli Lilly Company, which is reflected in its stock price. It is based on Eli Lilly's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Eli Lilly and helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors: Eli Lilly Total Value Analysis
Eli Lilly and is now expected to have takeover price of 1.91 T with market capitalization of 1.82 T, debt of 15.35 B, and cash on hands of 3.06 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Eli Lilly fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.91 T | 1.82 T | 15.35 B | 3.06 B |
Eli Lilly Investor Information
The company has Price/Earnings To Growth (PEG) ratio of 2.07. Eli Lilly last dividend was issued on the 14th of February 2023. The entity had 1:15 split on the 20th of November 2022. Based on the key measurements obtained from Eli Lilly's financial statements, Eli Lilly and is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Eli Lilly Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eli Lilly has an asset utilization ratio of 58.48 percent. This suggests that the Company is making R$0.58 for each dollar of assets. An increasing asset utilization means that Eli Lilly and is more efficient with each dollar of assets it utilizes for everyday operations.Eli Lilly Profitability Analysis
The company reported the revenue of 28.54 B. Net Income was 6.24 B with profit before overhead, payroll, taxes, and interest of 21.91 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Eli Lilly's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Eli Lilly and how it compares across the competition.
About Eli Lilly Valuation
The stock valuation mechanism determines Eli Lilly's current worth on a weekly basis. Our valuation model uses a comparative analysis of Eli Lilly. We calculate exposure to Eli Lilly's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eli Lilly's related companies.Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. LILLY DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 34690 people.
8 Steps to conduct Eli Lilly's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Eli Lilly's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Eli Lilly's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Eli Lilly's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Eli Lilly's revenue streams: Identify Eli Lilly's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Eli Lilly's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Eli Lilly's growth potential: Evaluate Eli Lilly's management, business model, and growth potential.
- Determine Eli Lilly's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Eli Lilly's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |